Chicago, Illinois, U.S., September 30, 2026
AbbVie is presenting new clinical and real-world evidence across multiple immune-mediated skin diseases at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, highlighting continued research into treatments for patients with chronic dermatologic conditions. The company’s presentations include data spanning atopic dermatitis, psoriasis, hidradenitis suppurativa and other immune-mediated skin diseases, with research examining efficacy, safety, treatment durability and real-world patient outcomes. The findings add to AbbVie’s broader dermatology research program and provide additional evidence on the use of its established and investigational therapies across different patient populations.
AbbVie Presents New Clinical Dermatology Data
At the 2026 EADV Congress, AbbVie is showcasing data from clinical trials and real-world evidence programs evaluating therapies for several immune-mediated dermatological diseases. The company said the presentations include analyses examining treatment response, long-term disease control and patient-reported outcomes. Such evidence is important in chronic inflammatory skin diseases because treatment goals extend beyond short-term symptom improvement to sustained control of disease activity, quality of life and reduction of treatment burden. The congress provides an international forum for researchers and dermatologists to review emerging evidence and discuss evolving treatment approaches in dermatology. AbbVie’s research portfolio includes therapies targeting important inflammatory pathways involved in dermatologic disease. Among the company’s established medicines is RINVOQ® (upadacitinib), a Janus kinase inhibitor approved for several inflammatory conditions, including certain dermatologic indications. The company is also developing and studying additional targeted treatments designed to address unmet needs in immune-mediated skin diseases. Data presented at EADV are intended to expand understanding of treatment effectiveness and safety across different disease stages and patient populations, while real-world analyses provide information about how therapies perform outside controlled clinical-trial environments.
Research Covers Atopic Dermatitis and Psoriasis
A key focus of the company’s EADV presence is atopic dermatitis, a chronic inflammatory skin disease characterized by itching, skin inflammation and recurrent symptoms. AbbVie is presenting clinical evidence evaluating treatment outcomes and longer-term disease control in patients receiving targeted therapies. The company is also highlighting research in psoriasis, another immune-mediated inflammatory condition affecting millions of people worldwide. Clinical and real-world evidence can help researchers understand how treatment responses vary between patients and how disease control develops over longer periods of therapy. The research also addresses hidradenitis suppurativa (HS), a chronic inflammatory skin disease associated with painful nodules, abscesses and recurrent lesions. AbbVie has developed a substantial clinical development program in HS, including research evaluating biologic and targeted therapies. Real-world evidence is particularly valuable in HS because disease severity, treatment history and patient experiences can vary considerably. By presenting clinical-trial and observational data together, researchers can build a broader picture of treatment outcomes and potential long-term disease-management strategies.
Advertisement
Real-World Evidence Supports Long-Term Care
Beyond randomized clinical trials, AbbVie is presenting real-world evidence designed to complement controlled clinical research. Real-world studies can provide information about treatment persistence, effectiveness, safety and patient experiences across broader populations than those typically included in clinical trials. These data can help researchers and healthcare professionals understand how therapies perform under routine clinical conditions and may identify treatment patterns that warrant additional investigation. AbbVie said its dermatology research strategy incorporates both clinical and real-world evidence to better understand patient needs and treatment outcomes across immune-mediated skin diseases.
The company’s presence at EADV reflects its continuing investment in dermatology research and development, with a focus on conditions where chronic inflammation can substantially affect patients’ physical and emotional well-being. The new evidence presented at the 2026 congress adds to the scientific understanding of targeted approaches for immune-mediated skin diseases and demonstrates the importance of evaluating therapies through both controlled trials and real-world clinical experience. Further peer-reviewed analyses and longer-term follow-up will continue to provide insight into the durability, safety and effectiveness of these treatment approaches.
Source: AbbVie press release
